Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02185690 |
| Title | A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung |
| Acronym | MEK162 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | University Health Network, Toronto, Novartis |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Cross Cancer Institute | Edmonton | Alberta | T6G1Z2 | Canada | Details | |
| Juravinski Cancer Centre | Hamilton | Ontario | L8V 5C2 | Canada | Details | |
| The Ottawa Hospital Regional Cancer Centre | Ottawa | Ontario | K1G 3Y9 | Canada | Details | |
| Princess Margaret Cancer Centre | Toronto | Ontario | M5G2M9 | Canada | Details |